Teladoc Stock Surges as Deutsche Bank Calls Shares "Compelling" and Sees Exit Upside
Deutsche Bank upgrades Teladoc Health to Buy from Hold with $11 price target, calling valuation compelling amid BetterHelp stabilization and potential exit upside.
/ 894 items
#Healthcare↓
Mineralys Shares Fall After FDA Accepts NDA for Lorundrostat – Explore-OSA Misses Primary Endpoint but Delivers Strong BP Reduction
Mineralys receives FDA acceptance of NDA for lorundrostat for hypertension. PDUFA target date: December 22, 2026. Explore-OSA missed primary endpoint but demonstrated meaningful BP reduction.
Vertex’s Povetacicept Hits Primary + All Secondary Endpoints in Phase 3 IgAN Trial
Vertex Pharmaceuticals' povetacicept succeeds in Phase 3 RAINIER trial for IgA nephropathy with 52% proteinuria reduction. Positive safety data and FDA submission planned soon.
FDA Clears Path for Haduvio, But Trevi’s “Safe” Two-Trial Plan Sends TRVI Down
Trevi Therapeutics shares plunged despite positive FDA alignment for Haduvio in IPF chronic cough. Plans for two Phase 3 trials (instead of one) triggered sell-off; Stifel holds Buy rating on the de-risked program.
Relmada Therapeutics Stock Surges After Strong NDV-01 Bladder Cancer Data and $160 Million Raise
Relmada shares jumped sharply after positive 12-month Phase 2 trial data for NDV-01 in bladder cancer and announcement of $160M financing to advance development.
H.C. Wainwright: Roche’s “Disappointing” persevERA Failure Is Not a Full Read-Through for Olema
H.C. Wainwright calls Roche’s persevERA trial disappointing but says it’s not a full readthrough for Olema Oncology. Different CDK4/6 inhibitor (ribociclib) may favor palazestrant in OPERA-02.